Headache Flashcards
Types of overall headaches
Primary
-Migraine
-Tension-type
Related to a disease (secondary)
Epidemiology of migraine
Occurs in 17.1% of women and 5.6% of men
After age 12, females 2-3x more likely to experience
Prevalence highest between ages 18-44
Pts that have less income and education are more likely to experience migraines
Pathophysiology of migraine
Genetic factors play an important role in susceptibility
Partially a neurovascular process
-Caused by changes in trigeminal nerve, decrease in 5-HT, and cranial vasodilation
Migraine without aura
At least 5 attacks
HA lasts 4-72 hrs and has 2 of the following characteristics
-Unilateral location, pulsating quality, moderate or severe intensity, and aggravation by or avoidance of routine physical activity
During HA at least 1 must be present and not attributed to another disorder
-N/V, photophobia, phonophobia
Increased risk for ischemic stroke
Migraine with aura
At least 2 attacks
Fulfills criteria for typical, hemiplegic, or basilar-type aura
Not attributed to another disorder
Aura
Evolves over 5-20 mins, lasts <60 mins
Most often visual, but can also be sensory and motor
Must have at least one of the following
-One symptom that develops gradually over at least 5 mins or different symptoms that occur in succession or both
Visual positive sx of aura
Flickering lights, spots or lines
Visual negative sx of aura
Loss of vision
Premonitory sx- neurologic
Phonophobia
Photophobia
Hypersomnia
Difficulty concentrating
Premonitory sx- psychological
Anxiety Depression Irritability Drowsiness Fatigue
Premonitory sx- autonomic
Polyuria
Diarrhea
Constipation
Premonitory sx- constitutional
Stiff neck Yawning Thirst Food cravings Anorexia
Resolution phase of migraine
Once HA pain fades Tiredness Exhaustion Irritability Scalp tenderness Mood changes
Assessment of migraines
HA hx HA triggers Physical exam Neuroimaging- not routine, only in atypical presentation Identify HA diagnostic alarms
HA triggers
Fatigue Alcohol Tobacco smoke Weather changes MSG Caffeine
Acute tx goals- migraine
Treat migraine attacks rapidly and consistently without recurrence
Restore pt’s ability to function
Minimize use of backup and rescue medications
Minimize use of backup and rescue medications
Optimize self-care for overall management
Be cost-effective in overall management
Cause minimal or no adverse effects
Medication overuse
One of the most common causes of daily chronic HA
Results in a pattern of increasing HA frequency
HA returns as medication wears off
Discontinuation of the offending agent leads to a decrease in HA frequency and severity
Limit use of acute therapies to 10 days/mo
Nonpharmacologic tx of migraine
Application of ice to head
Periods of rest or sleep
Avoidance of common and personal triggers
Behavioral therapy
Acute tx of migraines
Migraine-specific -Ergots -Triptans Nonspecific -Analgesics --OTC combo product -NSAIDS -Antiemetics -Corticosteroids
Regimen of acute tx for migraines
Should be given at the FIRST sign of sx
Migraine-specific medications used for more severe sx or sx unresponsive to NSAIDs/OTC analgesics
Ergot alkaloids
Consider for moderate to severe migraine attacks
Ergotamine tartrate and dihydroergotamine
MOA: nonselective 5-HT receptor agonists
-Constrict intracranial blood vessels
-Inhibit the development of neurogenic inflammation in the trigeminovascular system
Ergotamine tartrate (Cafergot)
Routes: oral, SL, rectal
Oral and rectal forms contain caffeine
Has both a daily and weekly maximum dose
Dosed at onset of sx and every 30-60 mins as needed
Dihydroergotamine (Migranal)
Routes: intranasal, IM, SQ, IV
Pts can be trained to give IM or SQ at home
Adverse effects of ergot alkaloids
Nausea, vomiting, diarrhea Abdominal pain Weakness Fatigue Paresthesias Muscle pain Chest tightness
Contraindications of ergot alkaloids
Renal or hepatic failure Coronary, cerebral, or peripheral vascular disease Uncontrolled htn Sepsis Nursing or pregnant women
Triptans
First line for mild to severe migraine
Typically want to treat at least 2-3 attacks before judging efficacy
MOA of triptans
5-HT (1b/1d) receptor agonists
Inhibit release of vasoactive peptide
Promote vasoconstriction
Block pain pathways in the brainstem
Contraindications of triptans
Hx of ischemic heart disease
Uncontrolled htn
Cerebrovascular disease
Hemiplegic and basilar migraine
Drug interactions of triptans
Do not give within 24 hrs of ergotamine derivatives
SSRIs/SNRIs potential to cause serotonin syndrome
Serotonin syndrome
Muscle rigidity, hypothermia, sweating
Adverse effects of triptans
Paresthesias Fatigue Dizziness Flushing Warm sensations Somnolence
Local SQ effects of triptans
Injection site reactions
Intranasal adverse effects of triptans
Taste perversion
Nasal discomfort
Second generation triptans
Almotriptan Eletriptan Frovatriptan Naratriptan Rizatriptan Zolmitriptan
Sumatriptan (Imitrex) oral dosage
25 mg, 50mg, 100mg
Repeat after 2 hrs
Sumatriptan (Imitrex) nasal dosage:
5, 10, 20mg
Repeat after 2 hrs
Sumatriptan (Imitrex) SQ dosage
4mg, 6mg
Repeat after 1 hr
Sumatriptan (Imitrex) max oral daily dose
200mg